Literature DB >> 12736375

The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20.

Vishwa Deo Trivedi1, Shu-Fang Cheng, Cheng-Wei Wu, Radhakrishnan Karthikeyan, Chen-Jui Chen, Ding-Kwo Chang.   

Abstract

A number of peptides and peptide analogs derived from the membrane proximal region of gp41 ectodomain are found to be effective inhibitors of human immunodeficiency virus type 1 (HIV-1)-mediated fusion events. One of them, T20 (aa 638-673), was found disordered and sparingly soluble in water, but became soluble upon mixing with selected, structured peptides from the amino terminal heptad repeat (HR1) region of gp41 using a simple and sensitive method of reduction in the scattering of T20 suspension. From the results on mapping the locus of interaction with T20 by employing partially overlapping peptides derived from HR1, it was concluded that the LLSGIV segment was a critical docking site for the C-terminal peptide of gp41 in its putative inhibitory action consistent with a previous fluorescence study. It was also found that peptides capable of solubilizing T20 dispersion have a high content of helix, as well as beta-strand, conformation in aqueous solution. Specificity of T20/HR1-derived peptide binding was ascertained by using a scrambled sequence of a T20-active peptide and a plateau in scattering reduction of T20 suspension with variation in the concentration of a T20-active HR1 peptide. Implications on the mechanism of T20 inhibition and the sequence of folding of the gp41 core structure are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736375     DOI: 10.1093/proeng/gzg036

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  17 in total

1.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

2.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Neutralization of HIV-1 by redirection of natural antibodies.

Authors:  Maria F Perdomo; Michael Levi; Matti Sällberg; Anders Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

4.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

5.  Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Authors:  Emmanuel Desmezieres; Nidhi Gupta; Russell Vassell; Yong He; Keith Peden; Lev Sirota; Zhongning Yang; Paul Wingfield; Carol D Weiss
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

7.  Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Authors:  Felix G Hermann; Lisa Egerer; Frances Brauer; Christian Gerum; Harald Schwalbe; Ursula Dietrich; Dorothee von Laer
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

8.  Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.

Authors:  Dirk Eggink; Johannes P M Langedijk; Alexandre M J J Bonvin; Yiqun Deng; Min Lu; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2009-07-17       Impact factor: 5.157

9.  Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

Authors:  Yuxian He; Jianwei Cheng; Jingjing Li; Zhi Qi; Hong Lu; Mingxin Dong; Shibo Jiang; Qiuyun Dai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.